Literature DB >> 21155900

Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.

Undine A Gerlach, Constanze Schoenemann, Nils Lachmann, Martin Koch, Andreas Pascher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21155900     DOI： 10.1111/j.1432-2277.2010.01203.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


× No keyword cloud information.
  4 in total

Review 1.  Chronic Rejection After Intestinal Transplant: Where Are We in Order to Avert It?

Authors:  Augusto Lauro; Mihai Oltean; Ignazio R Marino
Journal:  Dig Dis Sci       Date:  2018-01-11       Impact factor: 3.199

Review 2.  Intestinal Transplant Inflammation: the Third Inflammatory Bowel Disease.

Authors:  Alexander Kroemer; Christopher Cosentino; Jason Kaiser; Cal S Matsumoto; Thomas M Fishbein
Journal:  Curr Gastroenterol Rep       Date:  2016-11

Review 3.  Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine.

Authors:  Taizo Hibi; Masahiro Shinoda; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-05-16       Impact factor: 2.500

Review 4.  Updates on antibody-mediated rejection in intestinal transplantation.

Authors:  Guo-Sheng Wu
Journal:  World J Transplant       Date:  2016-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.